
First Patent Dosed With Pocenbrodib in Trial for Metastatic Prostate Cancer
The first patent has been dosed in the phase 1b/2a clinical trial P300-02-001, which is evaluating pocenbrodib alone, and in combination with Zytiga (abiraterone acetate), Lynparza (olaparib) or Pluvicto (177Lu-PSMA-617) in patients with metastatic …